EQL Pharma's CFO has chosen to leave her position
EQL Pharma AB's (publ) Chief Financial Officer (CFO) Jennie Sterning has chosen to leave her position. Jennie has been active in EQL Pharma since 2007 and CFO since 2016. Jennie will remain as CFO until mid-July.
- During her time at EQL Pharma, Jennie has built and developed EQL's finance function. She has also implemented financial management and the GDPR regulations within EQL. Recently, she has focused on the conversion to IFRS and the preparations for EQLs move to Nasdaq Stockholm's main exchange. I want to thank her for an invaluable effort for many years with us. We wish her best of luck with her new challenges, says Christer Fåhraeus, CEO of EQL Pharma.
A process to recruit a new CFO will begin soon. Emanuel Eriksson will take over as acting CFO during the period from Jennie Sterning's last day until a new long-term CFO is in place. Emanuel has a degree in business administration from Lund University with a focus on Technology Management. He has held senior positions in banking as a company manager and in acquisition financing (M&A). Emanuel is currently investment manager for Fårö Capital, where he has coordinated several IPOs in the past year. He has solid experience of the stock market and investor relations.
For further information, please contact:
Christer Fåhraeus
CEO, EQL Pharma AB (publ)
Phone: +46 (0) 705 – 60 90 00
E-mail: christer.fahraeus@eqlpharma.com
Website: www.eqlpharma.com
Eql Pharma AB (Publ) briefly
EQL Pharma AB specializes in developing and selling generics, ie pharmaceuticals that are medically equivalent to reference pharmaceuticals. The company currently has upwards of 20 niche generics (ie generics with limited competition apart from the reference pharmaceutical) approved in the Nordic markets. In addition to these, there is a significant pipeline of additional niche generics for launch in 2021 and beyond. The business is currently entirely focused on prescription pharmaceuticals, including hospital products, in the Nordic region and in selected European markets. EQL Pharma AB conducts its operations in Lund and is listed on the Spotlight Stock Market. EQL Pharma AB conducts extensive development work in collaboration with leading contract manufacturers and pharmaceutical companies in the EU and Asia, among others.